Director dealings: Victoria non-exec invests, Faron Pharma CFO sells entire holding
13th Jan 2026 13:03
(Sharecast News) - Shares in Victoria saw director support on Tuesday, after the group disclosed that non-executive director Steve Callaghan purchased 260,000 ordinary shares at 37.93p each on 9 January.
Read moreFaron issuing second tranche of unsecured convertible bonds
11th Dec 2025 16:32
(Sharecast News) - Faron Pharmaceuticals said on Thursday that its board had approved the issue of the second tranche of its amortising senior unsecured convertible bonds to an entity managed by Heights Capital Management, raising €10m to extend its cash runway and strengthen its financial position ahead of a planned registrational study in high-risk myelodysplastic syndromes.
Read moreFaron Pharmaceuticals appoints new finance chief
1st Dec 2025 11:48
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Jurriaan Dekkers as its chief financial officer on Monday, strengthening its senior leadership team as the clinical-stage biotech prepared its lead drug candidate, bexmarilimab, for registrational studies.
Read moreFaron strengthens bexmarilimab potential with fresh trial data
20th Oct 2025 10:04
(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab, strengthening the drug's profile as a treatment for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
Read moreFaron narrows first-half losses as it advances its lead asset
27th Aug 2025 08:56
(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in high-risk myelodysplastic syndromes (HR-MDS).
Read moreFaron secures FDA pathway for lead cancer therapy
18th Aug 2025 11:44
(Sharecast News) - Faron Pharmaceuticals said on Monday that it has secured a clear regulatory pathway for the potential approval of its lead cancer therapy bexmarilimab, following positive feedback from the US Food and Drug Administration.
Read moreFaron Pharmaceuticals appoints chief business officer
21st May 2025 14:31
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as the clinical-stage biopharma firm sharpened its focus on commercial strategy, business development and market access.
Read moreFaron enters financing arrangement with Heights Capital Management entity
3rd Apr 2025 10:28
(Sharecast News) - Faron Pharmaceuticals announced on Thursday that it has entered into a financing arrangement with an entity managed by Heights Capital Management for up to €35m in convertible bonds, issuing an initial €15m tranche to repay existing debt and bolster its financial position ahead of a key clinical readout.
Read moreFaron identifies final patient in BEXMAB phase two study
31st Jan 2025 11:29
(Sharecast News) - Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study in refractory or relapsed myelodysplastic syndrome (r/r MDS) and its phase one and two study in frontline high-risk (HR) MDS.
Read moreFaron Pharmaceuticals reports regulatory progress in the UK
2nd Dec 2024 11:50
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced significant regulatory progress in the UK for its lead asset bexmarilimab on Monday.
Read moreFaron announces promising MDS trial results
27th Nov 2024 11:39
(Sharecast News) - Faron Pharmaceuticals announced promising interim phase two results from its 'BEXMAB' trial on Wednesday, targeting relapsed or refractory myelodysplastic syndrome (r/r MDS) patients.
Read moreFaron Pharmaceuticals files new patent for Clever-1
11th Nov 2024 13:52
(Sharecast News) - Faron Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in immunotherapies for cancer and inflammatory diseases, announced the filing of a new patent application for the use of soluble Clever-1 in targeting T-cell inactivation on Monday, with potential applications in treating autoimmune diseases and inflammatory disorders.
Read moreFaron Pharmaceuticals candidate gets FDA fast track designation
27th Aug 2024 13:00
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that its lead candidate, bexmarilimab, has been granted fast track designation by the US Food and Drug Administration (FDA), for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine.
Read moreFaron gets positive FDA feedback on bexmarilimab study plans
11th Jul 2024 11:48
(Sharecast News) - Faron Pharmaceuticals announced positive feedback from the FDA regarding the clinical development plan for its drug candidate bexmarilimab, aimed at treating myelodysplastic syndrome (MDS), on Thursday.
Read moreFaron Pharmaceuticals extends funding agreement with IPF
30th Apr 2024 16:33
(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support as it progressed towards securing longer-term funding.
Read more